Evidence map›Paper›PMID 36232946›Full record

ArticleInternational journal of molecular sciences2022

Homozygous CRISPR/Cas9 Knockout Generated a Novel Functionally Active Exon 1 Skipping XPA Variant in Melanoma Cells.

Veronika Banicka, Marie Christine Martens, Rüdiger Panzer, David Schrama, Steffen Emmert, Lars Boeckmann, Alexander Thiem

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 56% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Veronika BanickaClinic and Policlinic for Dermatology and Venereology, University Medical Center Rostock, 18057 Rostock, Germany.ORCID 0000-0002-7545-5400
Marie Christine MartensClinic and Policlinic for Dermatology and Venereology, University Medical Center Rostock, 18057 Rostock, Germany.
Rüdiger PanzerClinic and Policlinic for Dermatology and Venereology, University Medical Center Rostock, 18057 Rostock, Germany.
David SchramaDepartment of Dermatology, Venereology and Allergology, University Hospital Würzburg, 97080 Würzburg, Germany.ORCID 0000-0002-6931-8194
Steffen EmmertClinic and Policlinic for Dermatology and Venereology, University Medical Center Rostock, 18057 Rostock, Germany.
Lars BoeckmannClinic and Policlinic for Dermatology and Venereology, University Medical Center Rostock, 18057 Rostock, Germany.ORCID 0000-0003-0098-6546
Alexander ThiemClinic and Policlinic for Dermatology and Venereology, University Medical Center Rostock, 18057 Rostock, Germany.ORCID 0000-0001-9504-4281
University of Rostock · DEUniversitätsklinikum Würzburg · DE

Funding

Forschungsförderung der Universitätsmedizin Rostock FORUNHiege Foundation-the German Skin Cancer Foundation
6 · The paper itself

Abstract

Defects in DNA repair pathways have been associated with an improved response to immune checkpoint inhibition (ICI). In particular, patients with the nucleotide excision repair (NER) defect disease Xeroderma pigmentosum (XP) responded impressively well to ICI treatment. Recently, in melanoma patients, pretherapeutic XP gene expression was predictive for anti-programmed cell death-1 (PD-1) ICI response. The underlying mechanisms of this finding are still to be revealed. Therefore, we used CRISPR/Cas9 to disrupt XPA in A375 melanoma cells. The resulting subclonal cell lines were investigated by Sanger sequencing. Based on their genetic sequence, candidates from

Indexed as

MelanomaXeroderma PigmentosumXeroderma Pigmentosum Group A ProteinCRISPR-Cas SystemsDNA DamageDNA RepairExonsHumansImmune Checkpoint InhibitorsProgrammed Cell Death 1 ReceptorUltraviolet RaysImmune Checkpoint InhibitorsProgrammed Cell Death 1 ReceptorXeroderma Pigmentosum Group A ProteinXPA protein, humanA375CRISPRDNA repairknockoutmelanomanucleotide excision repairprotein variantXPA

Identifiers

PMID36232946
PMCPMC9569948
OpenAlexW4303699338

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.